Postoperative radiotherapy for lung cancer: Is it worth the controversy?

被引：24

作者：

Billiet, Charlotte ^{[1
,2
]}

Peeters, Stephanie ^{[1
]}

Decaluwe, Herbert ^{[3
,4
]}

Vansteenkiste, Johan ^{[4
,5
]}

Mebis, Jeroen ^{[2
,6
]}

De Ruysscher, Dirk ^{[1
,7
]}

机构：

[1] Katholieke Univ Leuven, Univ Leuven, Dept Radiat Oncol, B-3000 Louvain, Belgium

[2] Hasselt Univ, Fac Med & Life Sci, Martelarenlaan 42, B-3500 Hasselt, Belgium

[3] Katholieke Univ Leuven, Univ Leuven, Dept Thorac Surg, B-3000 Louvain, Belgium

[4] Leuven Lung Canc Grp, B-3000 Louvain, Belgium

[5] Katholieke Univ Leuven, Univ Leuven, Dept Pneumol, Resp Oncol Unit, B-3000 Louvain, Belgium

[6] Jessa Hosp, Dept Med Oncol, B-3500 Hasselt, Belgium

[7] Maastricht Univ, Med Ctr, GROW, Dept Radiat Oncol MAASTRO, Maastricht, Netherlands

来源：

CANCER TREATMENT REVIEWS | 2016年 / 51卷

关键词：

Post-operative radiotherapy; Non-small-cell lung cancer; Review; MICROSCOPIC RESIDUAL DISEASE; RADIATION-THERAPY; PHASE-III; STAGE-II; INDUCTION CHEMOTHERAPY; ADJUVANT CHEMOTHERAPY; INTERCURRENT DISEASE; SURGICAL RESECTION; HODGKINS-DISEASE; SURVIVAL;

D O I：

10.1016/j.ctrv.2016.10.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Introduction: The role of postoperative radiation therapy (PORT) in patients with completely resected non-small cell lung cancer (NSCLC) with pathologically involved mediastinal lymph nodes (N2) remains unclear. Despite a reduction of local recurrence (LR), its effect on overall survival (OS) remains unproven. Therefore we conducted a review of the current literature. Methods: To investigate the benefit and safety of modern PORT, we identified published phase III trials for PORT. We investigated modern PORT in low-risk (ypN0/1 and RO) and high-risk (ypN2 and/or R1/2) patients with stage III-N2 NSCLC treated with induction chemotherapy and resection. Results: Seventeen phase III trials using PORT were selected. Of all PORT N2 studies, 4 were eligible for evaluation of LR, all in high-risk patients only. In these high-risk patients receiving PORT, the mean LR rate at 5 years was 20.9% (95% CI 16-24). Two trials were suitable to assess LR rates after chemotherapy and surgery without PORT. In these low-risk patients, the mean 5-year LR was 33.1% (95% CI 27-39). No significant difference in non-cancer deaths between PORT vs. non-PORT patients was observed in N2 NSCLC. Conclusion: PORT is worth the controversy because data illustrate that PORT may increase the OS. However, prospective randomized trials are needed to verify this. (C) 2016 Elsevier Ltd. All rights reserved.

引用

页码：10 / 18

页数：9

共 64 条

[1]

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial [J].

Albain, Kathy S. ;

Swann, R. Suzanne ;

Rusch, Valerie W. ;

Turrisi, Andrew T., III ;

Shepherd, Frances A. ;

Smith, Colum ;

Chen, Yuhchyau ;

Livingston, Robert B. ;

Feins, Richard H. ;

Gandara, David R. ;

Fry, Willard A. ;

Darling, Gail ;

Johnson, David H. ;

Green, Mark R. ;

Miller, Robert C. ;

Ley, Joanne ;

Sause, Willliam T. ;

Cox, James D. .

LANCET, 2009, 374 (9687) :379-386

[2]

ALBERTI W, 1995, BRIT MED J, V311, P899

[3]

Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal Downstaging After Induction Chemotherapy and Surgery [J].

Amini, Arya ;

Lou, Feiran ;

Correa, Arlene M. ;

Baldassarre, Randall ;

Rimner, Andreas ;

Huang, James ;

Roth, Jack A. ;

Swisher, Stephen G. ;

Vaporciyan, Ara A. ;

Lin, Steven H. .

ANNALS OF SURGICAL ONCOLOGY, 2013, 20 (06) :1934-1940

[4]

Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications [J].

Andre, F ;

Grunenwald, D ;

Pignon, JP ;

Dujon, A ;

Pujol, JL ;

Brichon, PY ;

Brouchet, L ;

Quoix, E ;

Westeel, V ;

Le Chevalier, T .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2981-2989

[5]

[Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]

[6]

Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis [J].

Askoxylakis, Vasileios ;

Tanner, Judith ;

Kappes, Jutta ;

Hoffmann, Hans ;

Nicolay, Nils H. ;

Rief, Harald ;

Debus, Juergen ;

Thomas, Michael ;

Bischof, Marc .

BMC CANCER, 2014, 14

[7]

Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data [J].

Auperin, A. ;

Le Chevalier, T. ;

Le Pechoux, C. ;

Pignon, J. P. ;

Tribodet, H. ;

Burdett, S. ;

Stewart, L. A. ;

Tierney, J. F. ;

Stephens, R. J. ;

Arriagada, R. ;

Higgins, J. P. ;

Johnson, D. H. ;

van Meerbeeck, J. ;

Parmar, M. K. B. ;

Souhami, R. L. ;

Bergman, B. ;

Dautzenberg, B. ;

Douillard, J. Y. ;

Dunant, A. ;

Endo, C. ;

Girling, D. J. ;

Imaizumi, M. ;

Kato, H. ;

Keller, S. M. ;

Kimura, H. ;

Knuuttila, A. ;

Kodama, K. ;

Komaki, R. ;

Kris, M. G. ;

Lad, T. ;

Mineo, T. ;

Park, J. H. ;

Piantadosi, S. ;

Pyrhonen, S. ;

Rosell, R. ;

Scagliotti, G. V. ;

Seymour, L. W. ;

Shepherd, F. A. ;

Spiro, S. G. ;

Strauss, G. M. ;

Sylvester, R. ;

Tada, H. ;

Tanaka, F. ;

Torri, V. ;

Wada, H. ;

Waller, D. ;

Xu, G. C. .

LANCET, 2010, 375 (9722) :1267-1277

[8]

Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer:: 5-year follow-up of a phase II study [J].

Betticher, DC ;

Schmitz, SFH ;

Tötsch, M ;

Hansen, E ;

Joss, C ;

von Briel, C ;

Schmid, R ;

Pless, M ;

Habicht, J ;

Roth, AD ;

Spiliopoulos, A ;

Stahel, R ;

Weder, W ;

Stupp, R ;

Egli, F ;

Furrer, M ;

Honegger, H ;

Wernli, M ;

Cerny, T ;

Ris, HB .

BRITISH JOURNAL OF CANCER, 2006, 94 (08) :1099-1106

[9]

Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial [J].